197 related articles for article (PubMed ID: 18633763)
1. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
[TBL] [Abstract][Full Text] [Related]
2. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
3. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension.
Kosch M; Levers A; Lang D; Bartels V; Rahn KH; Pavenstädt H; Hausberg M
Nephrol Dial Transplant; 2008 Jul; 23(7):2280-5. PubMed ID: 18194979
[TBL] [Abstract][Full Text] [Related]
5. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
[TBL] [Abstract][Full Text] [Related]
6. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
7. Reduction of age-associated arterial wall changes by low-dose valsartan.
Lunder M; Janic M; Sabovic M
Eur J Prev Cardiol; 2012 Dec; 19(6):1243-9. PubMed ID: 21933833
[TBL] [Abstract][Full Text] [Related]
8. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.
Hayoz D; Zappe DH; Meyer MA; Baek I; Kandra A; Joly MP; Mazzolai L; Haesler E; Periard D
J Clin Hypertens (Greenwich); 2012 Nov; 14(11):773-8. PubMed ID: 23126349
[TBL] [Abstract][Full Text] [Related]
9. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension.
Shargorodsky M; Leibovitz E; Lubimov L; Gavish D; Zimlichman R
Am J Hypertens; 2002 Dec; 15(12):1087-91. PubMed ID: 12460705
[TBL] [Abstract][Full Text] [Related]
10. Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension.
Okura T; Watanabe S; Kurata M; Manabe S; Koresawa M; Irita J; Enomoto D; Miyoshi K; Fukuoka T; Higaki J
Hypertens Res; 2007 Apr; 30(4):335-40. PubMed ID: 17541212
[TBL] [Abstract][Full Text] [Related]
11. Intrarenal and carotid hemodynamics in patients with essential hypertension.
Okura T; Watanabe S; Miyoshi K; Fukuoka T; Higaki J
Am J Hypertens; 2004 Mar; 17(3):240-4. PubMed ID: 15001198
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study.
Spanos G; Kalaitzidis R; Karasavvidou D; Pappas K; Siamopoulos KC
J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):315-21. PubMed ID: 23132848
[TBL] [Abstract][Full Text] [Related]
13. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Savoia C; Touyz RM; Volpe M; Schiffrin EL
Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of intima-media thickness and vascular elasticity of the common carotid artery in patients with isolated systolic hypertension using ultrasound radiofrequency-data technology.
Dan HJ; Wang Y; Zeng MX; Luan YY; Hu B
Clin Physiol Funct Imaging; 2011 Jul; 31(4):315-9. PubMed ID: 21672140
[TBL] [Abstract][Full Text] [Related]
16. Valsartan prevents neointimal hyperplasia after carotid artery stenting by suppressing endothelial cell injuries.
Suzuki H; Sano T; Umeda Y; Yamamoto A; Toma N; Sakaida H; Taki W
Neurol Res; 2015 Jan; 37(1):35-42. PubMed ID: 24938321
[TBL] [Abstract][Full Text] [Related]
17. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension.
Ariff B; Zambanini A; Vamadeva S; Barratt D; Xu Y; Sever P; Stanton A; Hughes A; Thom S
Stroke; 2006 Sep; 37(9):2381-4. PubMed ID: 16888272
[TBL] [Abstract][Full Text] [Related]
18. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension.
Manabe S; Okura T; Watanabe S; Fukuoka T; Higaki J
J Cardiovasc Pharmacol; 2005 Dec; 46(6):735-9. PubMed ID: 16306795
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
